A

argenx SE
D

ARGX

645.20
USD
-2.16
(-0.33%)
مغلق
حجم التداول
7,407
الربح لكل سهم
7
العائد الربحي
-
P/E
-827
حجم السوق
39,202,969,456
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    SNY
    SNY
    0.325
    (0.60%)
    54.445 USD
    U
    UCB
    -0.680
    (-2.09%)
    31.890 USD
    المزيد
الأخبار
المقالات

العنوان: argenx SE

القطاع: Healthcare
الصناعة: Biotechnology
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.